Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21939011 | 0.84 | CES2 (0.42) | ALDH1A1EPHX1SMN1; SMN2LMNACES2 | |
| SCHEMBL24146310 | 0.84 | NAAA (0.40) | EPHX1LMNA | |
| SCHEMBL5880920 | 0.82 | HPGD (0.50) | HPGDTP53ALDH1A1EPHX1SMN1; SMN2 | |
| SCHEMBL13332473 | 0.80 | HPGD (0.53) | HPGDTP53ALDH1A1EPHX1SMN1; SMN2 | |
| SCHEMBL3990546 | 0.80 | HPGD (0.53) | HPGDTP53ALDH1A1EPHX1SMN1; SMN2 | |
| SCHEMBL27753580 | 0.79 | LMNA (0.49) | HPGDALDH1A1EPHX1SMN1; SMN2LMNA | |
| SCHEMBL8986251 | 0.77 | NFE2L2 (0.42) | HPGDALDH1A1EPHX1SMN1; SMN2LMNA | |
| SCHEMBL25917202 | 0.76 | NAAA (0.37) | ALDH1A1EPHX1CES2CES1HSD11B1 | |
| SCHEMBL3993887 | 0.76 | CYP1A2 (0.41) | HPGDTP53EPHX1FKBP1ACES2 | |
| SCHEMBL8743871 | 0.75 | CYP1A2 (0.46) | HPGDALDH1A1EPHX1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, CLK2, DDRGK1 | HPGD 2536/4885TP53 321/4885ALDH1A1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.